<DOC>
	<DOCNO>NCT02275065</DOCNO>
	<brief_summary>This study investigate short-term antiviral potency , safety , plasma pharmacokinetics ( PK ) , PK/pharmacodynamic ( PD ) relationship ( dose-response relationship ) GS-9883 multiple dos antiretroviral ( ART ) treatment-naive adult subject subject ART-experienced currently ART therapy . Up 32 participant enrol study .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Antiviral Activity GS-9883 HIV-1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>No current prior antiHIV treatment , include antiretroviral medication receive prevention ( preexposure prophylaxis [ PrEP ] ) , postexposure prophylaxis ( PEP ) within 12 week screen Must 18 65 year age , inclusive date screen visit Plasma HIV1 RNA ≥ 10,000 copies/mL ≤ 400,000 copies/mL screen CD4+ cell count &gt; 200 cells/mm^3 Anticipated start HIV1 therapy study period Active participation another study investigational approve antiretroviral agent A new AIDSdefining condition diagnose within 30 day prior screen Subjects positive hepatitis C antibody screen Chronic hepatitis B virus ( HBV ) infection Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 42 day prior Day 1 ( baseline )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV-1 Infected</keyword>
	<keyword>Adults</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>